Delivery Order SPE2DR25D3012-SPE2DR26F4E0G
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $3,279.20 under a firm fixed price arrangement. The award, issued December 15, 2025, with completion targeted for December 16, 2025, represents a non-competitive set-aside delivery order executed through the company's existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $23,153.27 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on December 8, 2025, with completion scheduled for December 9, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor will perform this...
- The Defense Logistics Agency awarded a $23,192.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract, which represents a non-competitive delivery order under an existing indefinite delivery vehicle, is scheduled for completion by June 3, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $21.3K to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a completion date of December 3, 2025. This is a firm fixed-price, non-set-aside contract supporting federal medical procurement needs. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $1 billion and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $30,739.23 under a firm fixed-price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and was performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award with no set-aside designation, demonstrating AmerisourceBergen's capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $77,613.62. This non-set-aside competitive award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $6,558.40 under a firm fixed-price contract. The award, issued on November 10, 2025, with an ultimate completion date of November 12, 2025, represents a non-competitive delivery order supporting federal pharmaceutical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $16,002.89 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (quantity: 30 tablets). This firm fixed price delivery order, awarded on November 10, 2025, with completion targeted for November 12, 2025, was competitively awarded without set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the performing location for this contract. The award represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for RINVOQ ER 15 mg tablets (30-count units). The order, valued at $11,769.72 with a firm fixed price structure, was competitively awarded without set-aside designation and is scheduled for completion by September 16, 2025. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) at a ceiling value of $3,279.20. This firm fixed-price, non-set-aside delivery order represents a competitive procurement action with an ultimate completion date of December 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4E0GDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) valued at $81,736.87 under a firm fixed-price contract structure. The award, issued on December 23, 2025, with completion targeted for December 24, 2025, represents a non-competitive delivery order placement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location. This delivery order is a child contract issued against the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. This award reflects the ongoing operational demand for pharmaceutical products within the Defense Health Agency's supply chain and demonstrates AmerisourceBergen Drug Corp's critical role as a primary pharmaceutical vendor for federal military medical procurement. The company's extensive federal contract portfolio, characterized by competitively awarded delivery orders with firm fixed pricing across multiple therapeutic domains, underscores its capability to meet federal medical supply requirements. The broader SPE2DX IDC represents a strategic procurement approach enabling the Defense Logistics Agency to source diverse pharmaceutical and medical commodities globally in support of military readiness and healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $81.7k | 12/22/25 |